Cytogen Corp. said Monday that it has begun shippingcommercial quantities of OncoScint CR/OV, which was grantedmarketing approval by FDA in December.
Cytogen of Princeton, N.J., said it began shipping the monoclonalantibody-based diagnostic imaging agent for colorectal andovarian cancer to its co-promotion partner, KnollPharmaceuticals, a division of BASF K&F Corp., for nationaldistribution on Friday.
(c) 1997 American Health Consultants. All rights reserved.